Evidence map›Paper›PMID 38774379›Full record

ArticleEuropean heart journal. Digital health2024

Development and validation of risk prediction model for recurrent cardiovascular events among Chinese: the Personalized CARdiovascular DIsease risk Assessment for Chinese model.

Yekai Zhou, Celia Jiaxi Lin, Qiuyan Yu, Joseph Edgar Blais, Eric Yuk Fai Wan, Marco Lee, Emmanuel Wong, David Chung-Wah Siu, Vincent Wong, Esther Wai Yin Chan and 5 more

Abstract read
In one paragraph

Article in European heart journal. Digital health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yekai ZhouDepartment of Computer Science, The University of Hong Kong, Rm 301 Chow Yei Ching Building, Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, 999077, China.
Celia Jiaxi LinSchool of Nursing, The University of Hong Kong, 5/F Academic Building, 3 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, 999077, China.
Qiuyan YuCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, 999077, China.
Joseph Edgar BlaisCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, 999077, China.ORCID https://orcid.org/0000-0001-7895-198X
Eric Yuk Fai WanCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, 999077, China.ORCID https://orcid.org/0000-0002-6275-1147
Marco LeeCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, 999077, China.
Emmanuel WongDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, 999077, China.
David Chung-Wah SiuDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, 999077, China.
Vincent WongDepartment of Pharmacy, Queen Mary Hospital, Hospital Authority, Hong Kong Special Administrative Region, 999077, China.
Esther Wai Yin ChanCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, 999077, China.
Tak-Wah LamDepartment of Computer Science, The University of Hong Kong, Rm 301 Chow Yei Ching Building, Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, 999077, China.
William ChuiDepartment of Pharmacy, Queen Mary Hospital, Hospital Authority, Hong Kong Special Administrative Region, 999077, China.
Ian Chi Kei WongCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, 999077, China.
Ruibang LuoDepartment of Computer Science, The University of Hong Kong, Rm 301 Chow Yei Ching Building, Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, 999077, China.ORCID https://orcid.org/0000-0001-9711-6533
Celine Sze Ling ChuiSchool of Nursing, The University of Hong Kong, 5/F Academic Building, 3 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, 999077, China.ORCID https://orcid.org/0000-0003-1513-8726

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Cardiovascular disease (CVD) is a leading cause of mortality, especially in developing countries. This study aimed to develop and validate a CVD risk prediction model, Personalized CARdiovascular DIsease risk Assessment for Chinese (P-CARDIAC), for recurrent cardiovascular events using machine learning technique. Methods and results: Three cohorts of Chinese patients with established CVD were included if they had used any of the public healthcare services provided by the Hong Kong Hospital Authority (HA) since 2004 and categorized by their geographical locations. The 10-year CVD outcome was a composite of diagnostic or procedure codes with specific International Classification of Diseases, Ninth Revision, Clinical Modification. Multivariate imputation with chained equations and XGBoost were applied for the model development. The comparison with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2°P) and Secondary Manifestations of ARTerial disease (SMART2) used the validation cohorts with 1000 bootstrap replicates. A total of 48 799, 119 672 and 140 533 patients were included in the derivation and validation cohorts, respectively. A list of 125 risk variables were used to make predictions on CVD risk, of which 8 classes of CVD-related drugs were considered interactive covariates. Model performance in the derivation cohort showed satisfying discrimination and calibration with a C statistic of 0.69. Internal validation showed good discrimination and calibration performance with C statistic over 0.6. The P-CARDIAC also showed better performance than TRS-2°P and SMART2. Conclusion: Compared with other risk scores, the P-CARDIAC enables to identify unique patterns of Chinese patients with established CVD. We anticipate that the P-CARDIAC can be applied in various settings to prevent recurrent CVD events, thus reducing the related healthcare burden.

Indexed as

Cardiovascular diseasesMachine learningRecurrent cardiovascular eventsRisk prediction score

Identifiers

PMID38774379
PMCPMC11104455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.